Sun Yat-Sen University Cancer Center

A shortened adjuvant chemotherapy regimen improved outcomes for infants with unilateral pathologic high-risk retinoblastoma, according to study results.

Fruquintinib plus paclitaxel significantly improved PFS in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to results from a phase 3 trial presented during an ASCO Plenary Series session.

CHICAGO — When added to induction chemotherapy and concurrent chemoradiotherapy, sintilimab conferred a 41% reduction in risk for disease recurrence or death among patients with high-risk locoregionally advanced nasopharyngeal carcinoma.

The addition of interferon alfa to temozolomide significantly extended survival among patients with newly diagnosed high-grade gliomas, according to data published in JAMA Network Open.

CHICAGO — Intensity-modulated radiotherapy conferred disease control and survival outcomes comparable to concurrent chemoradiotherapy but with less toxicity among patients with low-risk nasopharyngeal carcinoma, according to study results.

Capecitabine maintenance therapy significantly prolonged PFS among patients with newly diagnosed metastatic nasopharyngeal carcinoma who achieved disease control after capecitabine-containing induction chemotherapy, according to a study.

The addition of tislelizumab to chemotherapy conferred a clinically meaningful PFS benefit among patients with recurrent or metastatic nasopharyngeal cancer, according to updated results of the randomized phase 3 RATIONALE-309 study.

Lenvatinib plus transarterial chemoembolization prolonged survival and improved response rates among patients in China with advanced hepatocellular carcinoma, according to study results presented at ASCO Gastrointestinal Cancers Symposium.

Hepatic arterial infusion chemotherapy of FOLFOX regimens demonstrated superior efficacy and OS than sorafenib as first-line treatment of advanced hepatocellular carcinoma with a heavy intrahepatic tumor burden.

Adding toripalimab to gemcitabine-cisplatin chemotherapy significantly improved PFS and overall response rates and induced longer-lasting responses than chemotherapy alone as first-line therapy for advanced nasopharyngeal carcinoma.